Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) just unveiled an update.
On November 21, 2025, Shuttle Pharmaceuticals Holdings, Inc. announced the resignation of Timothy Lorber as Chief Financial Officer. In connection with his resignation, a Separation Agreement was established, allowing Mr. Lorber to provide part-time services until December 4, 2025, and remain available for consultation until February 8, 2026. Christopher Cooper, the Interim CEO, has taken over the CFO role while the company searches for a permanent replacement. The agreement includes a retention bonus for Mr. Lorber and the vesting of restricted stock units, reflecting a structured transition plan.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Average Trading Volume: 310,026
Technical Sentiment Signal: Sell
Current Market Cap: $2.16M
See more data about SHPH stock on TipRanks’ Stock Analysis page.